Literature DB >> 26324814

Therapeutic strategies in pneumonia: going beyond antibiotics.

Holger Müller-Redetzky1, Jasmin Lienau1, Norbert Suttorp1, Martin Witzenrath2.   

Abstract

Dysregulation of the innate immune system drives lung injury and its systemic sequelae due to breakdown of vascular barrier function, harmful hyperinflammation and microcirculatory failure, which contribute to the unfavourable outcome of patients with severe pneumonia. A variety of promising therapeutic targets have been identified and numerous innovative therapeutic approaches demonstrated to improve lung injury in experimental preclinical studies. However, at present specific preventive or curative strategies for the treatment of lung failure in pneumonia in addition to antibiotics are still missing. The aim of this mini-review is to give a short overview of some, but not all, adjuvant therapeutic strategies for pneumonia and its most important complications, sepsis and acute respiratory distress syndrome, and briefly discuss future perspectives.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26324814     DOI: 10.1183/16000617.0034-2015

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  8 in total

1.  Evaluation of Ventilation-Induced Lung Inflammation Through Multi-Scale Simulations.

Authors:  Israr Bin M Ibrahim; Ramana M Pidaparti; Kevin R Ward
Journal:  IEEE J Transl Eng Health Med       Date:  2017-12-27       Impact factor: 3.316

2.  Age, Period and Cohort Analysis of Rates of Emergency Department Visits Due to Pneumonia in Taiwan, 1998-2012.

Authors:  Shin-Hong Chen; I-Shiang Tzeng; Chou-Chin Lan; Jau-Yuan Chen; Chau Yee Ng; Yao-Chin Wang; Wen-Lin Su; Giou-Teng Yiang; Tsu-Yi Chen; Chih-Wei Wu; Po-Chun Hsieh; Chan-Yen Kuo; Meng-Yu Wu
Journal:  Risk Manag Healthc Policy       Date:  2020-09-04

Review 3.  Granulocyte-targeted therapies for airway diseases.

Authors:  Luciana P Tavares; Hong Yong Peh; Wan Shun Daniel Tan; Hadas Pahima; Pasquale Maffia; Ekaterini Tiligada; Francesca Levi-Schaffer
Journal:  Pharmacol Res       Date:  2020-05-04       Impact factor: 7.658

4.  Adjunctive therapy with the Tie2 agonist Vasculotide reduces pulmonary permeability in Streptococcus pneumoniae infected and mechanically ventilated mice.

Authors:  Aina Lask; Birgitt Gutbier; Olivia Kershaw; Geraldine Nouailles; Achim D Gruber; Holger C Müller-Redetzky; Steven Chackowicz; Douglas A Hamilton; Paul Van Slyke; Martin Witzenrath
Journal:  Sci Rep       Date:  2022-09-15       Impact factor: 4.996

Review 5.  Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group.

Authors:  Mathias W Pletz; Andreas Vestergaard Jensen; Christina Bahrs; Claudia Davenport; Jan Rupp; Martin Witzenrath; Grit Barten-Neiner; Martin Kolditz; Sabine Dettmer; James D Chalmers; Daiana Stolz; Norbert Suttorp; Stefano Aliberti; Wolfgang M Kuebler; Gernot Rohde
Journal:  Respir Res       Date:  2022-09-10

6.  Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia.

Authors:  Alexander P de Porto; Zhe Liu; Regina de Beer; Sandrine Florquin; Onno J de Boer; Rudi W Hendriks; Tom van der Poll; Alex F de Vos
Journal:  Mol Med       Date:  2019-01-15       Impact factor: 6.354

7.  Pneumonia in the face of COVID-19.

Authors:  Martin Witzenrath; Wolfgang M Kuebler
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-09-30       Impact factor: 5.464

8.  Neutrophil-Derived Extracellular Vesicles Activate Platelets after Pneumolysin Exposure.

Authors:  Eleftheria Letsiou; Luiz Gustavo Teixeira Alves; Matthias Felten; Timothy J Mitchell; Holger C Müller-Redetzky; Steven M Dudek; Martin Witzenrath
Journal:  Cells       Date:  2021-12-18       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.